Top Markets
#1 Derive Derive +15.92%
#2 Cross Cross +14.63%
#3 Glidr Glidr +10.10%
#4 Gama Token Gama Token +9.10%
#5 Based Based +5.46%
#6 Talus Network Talus Network +5.41%
#7 龙虾 (Lobster) 龙虾 (Lobster) +4.95%
#8 Cap Cap +4.91%
#9 TDCCP TDCCP +4.76%
#10 LEO Token LEO Token +4.69%
Coin of the day
Derive Derive
Settings
Language
ENGLISH
Currency
USD
Theme
Carmell Therapeutics Corporation Carmell Therapeutics Corporation

Carmell Therapeutics Corporation

CTCX
Rank in Stocks #36666
Carmell Therapeutics Corporation (CTCX) specializes in the creation of... Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.
Share Price
$0.117
Last synced: 2025-04-04
Market Cap
$2.45M
Change (1 day)
-13.59%
Change (1 year)
0.00%
Country
US
Trade Carmell Therapeutics Corporation (CTCX)

Category

Healthcare
Earnings for Carmell Therapeutics Corporation (CTCX)
Earnings in Jun 2026 TTM: $-6.79M
According to Carmell Therapeutics Corporation latest financial reports the company's current earnings are $-6.79M. In 2023 the company made an earning of $-16.21M, a decrease compared to its 2022 earnings that were of $-9.05M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Carmell Therapeutics Corporation from 2021 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $-6.79M -36.81%
2024 $-10.75M -33.68%
2023 $-16.21M 79.04%
2022 $-9.05M 2,647.97%
2021 $-329.38K 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -77,766.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -28,821.01%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -44,355.62%
BE